JEFFREY COSSMAN, M.D. - Corporate Board Profile

Precipio, Inc.

Filing Date	Source Excerpt
2017-12-29	Jeffrey Cossman, M.D. (4) Consists of 778 shares of Common Stock issuable upon the exercise of stock options that are exercisable or will become exercisable within 60 days after November 30, 2017.
2018-05-29	Jeffrey Cossman, M.D. 70 Director, Member of the Compensation Committee and the Nominating and Corporate Governance Committee 2017 2020 Director Summary Compensation Table Jeffrey Cossman 42,000 11,200 53,200
2018-11-27	Jeffrey Cossman, M.D. Consists solely of shares of Common Stock issuable upon the exercise of stock options that are exercisable or will become exercisable within 60 days after November 7, 2018.
2019-04-29	Jeffrey Cossman 42,000 2,068 5,170 2/16/2018 10.65 70,582 112,582
2020-04-29	Jeffrey Cossman, M.D. Director, Chair of the Nominating and Corporate Governance Committee. Director Summary Compensation Table: Jeffrey Cossman Fees Earned or Paid in Cash $25,667, Option Awards $10,200, Total $35,867.
2021-04-29	Jeffrey Cossman, M.D. Dr. Cossman, age 74, was appointed as director of the Company in September 2017. Dr. Cossman was a founder of and served as Chief Executive Officer and Chairman of the Board at United States Diagnostic Standards, Inc. from 2010 to 2014, and as a member of the Board of The Personalized Medicine Coalition from 2008 to 2014. Prior to that, he served as Chief Scientific Officer and as member of the Board of Directors of The Critical Path Institute, and as Medical Director of Gene Logic, Inc. He was Professor and Chairman of the Department of Pathology at Georgetown University Medical Center where he held the Oscar Benwood Hunter Chair of Pathology and he served as Senior Investigator in Hematopathology at the National Cancer Institute. From 2014, Mr. Cossman is serving as a medical advisor to Epigenomics AG. Dr. Cossman holds a B.S. from the University of Michigan and an M.D. from the University of Michigan Medical School. He is board-certified in pathology and trained in pathology and hematopathology at the University of Michigan, Stanford University and the National Institutes of Health. The Board believes that, as former chair of the department of pathology of Georgetown University, a premier academic institution, Dr. Cossman provides significant insight and guidance as to how the company should execute on its model. Furthermore, his experience in the molecular field is significant to the Company’s strategy.
2022-04-28	Jeffrey Cossman, M.D. Dr. Cossman, age 74, was appointed as a director of the Company in September 2017. From 2014 to 2022, Dr. Cossman was Medical Advisor for Epigenomics AG. from 2010 to 2014, Dr. Cossman was Founder, Chief Executive Officer and Chairman of the Board at United States Diagnostic Standards, Inc.. He is a Co-Founder of the Association for Molecular Pathology (AMP). He was a member of the Board of Directors of The Personalized Medicine Coalition from 2008 to 2014. Dr. Cossman served as Chief Scientific Officer and as member of the Board of Directors of The Critical Path Institute, and as Medical Director of Gene Logic, Inc. He was Professor and Chairman of the Department of Pathology at Georgetown University Medical Center where he was the Oscar Benwood Hunter Chair of Pathology. He served as Senior Investigator in Hematopathology at the National Cancer Institute. Dr. Cossman holds a B.S. from the University of Michigan and an M.D. from the University of Michigan Medical School. He is board-certified in Pathology and trained in Pathology and Hematopathology at the University of Michigan, Stanford University and the National Institutes of Health. The Board believes that, as former Chairman of the Department of Pathology of Georgetown University, a premier academic institution, Dr. Cossman provides significant insight and guidance as to how the company should execute on its model. Furthermore, his experience in the molecular diagnostics field is significant to the Company’s strategy.
2023-04-25	Jeffrey Cossman, M.D. Dr. Cossman, age 76, was appointed as a director of the Company in September 2017. ... The Nominating and Corporate Governance Committee currently consists of directors Dr. Cossman and Mr. Cohen. ... Director Summary Compensation Table The following table provides information regarding our compensation for non-employee directors during the fiscal year ended December 31, 2022. ... Jeffrey Cossman Fees Earned or Paid in Cash ($) 42,000 Option Awards ($) 59,200 Total ($) 101,200.
2024-04-29	Jeffrey Cossman, M.D. Dr. Cossman, age 76, was appointed as a director of the Company in September 2017. ... The Nominating and Corporate Governance Committee currently consists of directors Dr. Cossman, who serves as chairperson of the committee, and Ms. Valauri, each of whom has been determined by the Board to be independent under the Nasdaq listing standards. ... Director Summary Compensation Table The following table provides information regarding our compensation for non-employee directors during the fiscal year ended December 31, 2023. ... Jeffrey Cossman 42,000 Fees Earned or Paid in Cash, 17,805 Option Awards, 4,200 All Other Compensation, 64,005 Total.